Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011, for R&R Acquisition VI, Inc. (Note: The input metadata lists "ADMA BIOLOGICS, INC.", but the filing text explicitly identifies the registrant as R&R Acquisition VI, Inc.). The company is a Delaware corporation classified as a "blank check" company and a development stage entity. Its sole objective is to acquire or merge with an operating business. As of the reporting date, the company had not commenced any operations, had no revenues, and employed no full-time staff.
Key Financial Metrics
| Metric | Value (Nine Months Ended Mar 31, 2011) | Value (Three Months Ended Mar 31, 2011) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(14,780) | $(4,908) |
| Total Operating Expenses | $14,783 | $4,910 |
| Cash and Cash Equivalents | $16,192 (as of Mar 31, 2011) | N/A |
| Working Capital | $10,374 | N/A |
| Total Liabilities | $5,818 (Accrued expenses) | N/A |
| Stockholders' Equity | $10,374 | N/A |
| Shares Outstanding | 2,500,000 | 2,500,000 |
Note: The filing does not provide data on profit margins or debt ratios as the company has no revenue and no formal debt instruments, only accrued expenses.
Material Changes vs. Prior Period
- Operating Expenses: For the nine months ended March 31, 2011, total operating expenses were $14,783, an increase from $12,957 in the same period in 2010. This increase is attributed to higher professional and filing fees.
- Net Loss: The net loss for the nine-month period increased to $(14,780) from $(12,954) in the prior year.
- Liquidity: Cash and cash equivalents increased from $12,012 at June 30, 2010, to $16,192 at March 31, 2011. This increase was driven by $25,500 in contributed capital, which offset the net cash used in operating activities of $(21,320).
- Liabilities: Accrued expenses decreased from $12,358 at June 30, 2010, to $5,818 at March 31, 2011.
Outlook, Risks, and Management Commentary
- Business Plan: The company has no specific business plan other than to effect a business combination with an operating company. It does not intend to develop a market for its securities until a combination is concluded.
- Liquidity Risk: The company has no revenues and is dependent on future loans from stockholders or management to continue operations. There is no assurance that such funding will be available on acceptable terms.
- Operational Risk: Success is entirely dependent on the future performance of a single target business. The company lacks the resources to diversify operations or undertake multiple combinations.
- Management: Officers devote only part-time effort to the company. No full-time employees are anticipated while seeking a target. Current management is not expected to play a managerial role post-merger.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to risks inherent in the "blank check" model.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("ADMA BIOLOGICS, INC.") and the actual registrant name in the filing ("R&R Acquisition VI, Inc.").
- Confirm the company's status as a "shell company" and "blank check" entity with no active operations.
- Assess the sustainability of the $16,192 cash balance given the lack of revenue and reliance on contributed capital.
- Review the $5,818 in accrued expenses to understand outstanding obligations to service providers.
- Monitor for any announcements regarding a definitive agreement for a business combination, as the company's value is contingent on this event.